You are here

Heart Failure

 

The FDA has approved the first MRI conditional cardiac resynchronization therapy defibrillators (CRT-Ds) to treat patients with heart failure and reduce the risk of sudden cardiac arrest.

 

Recent Headlines

Novartis agrees to pay-for-performance agreements with insurers to cover heart failure drug

Novartis has entered into a pay-for-performance agreement with Cigna to cover sacubitril/valsartan (Entresto), a twice-daily oral medication to treat patients with heart failure and reduced ejection fraction. Aetna also signed a value-based agreement with Novartis based on the drug having similar results as shown in clinical trials, according to a Reuters report.

FDA approves Medtronic's MRI conditional CRT defibrillators for heart failure patients

The FDA has approved the first MRI conditional cardiac resynchronization therapy defibrillators (CRT-Ds) to treat patients with heart failure and reduce the risk of sudden cardiac arrest.

Exercising and dieting improves exercise capacity but not quality of life in older, obese heart failure patients

After a 20-week regimen that included an improved diet and/or an increased exercise regiment, obese, older adults with heart failure had an increase in exercise capacity, according to a randomized trial conducted at an urban academic medical center. However, the regimen did not have a significant effect on quality of life.

Age-adjusted heart failure-related deaths increase from 2012 to 2014

After declining for more than a decade, the age-adjusted rate for heart failure-related deaths increased from 2012 to 2014, according to a recent data brief from the National Center for Health Statistics.

Predicting 30-day readmissions for heart failure patients remains challenging

A model developed to predict 30-day readmissions for heart failure found that having patients self-report their socioeconomic, health status and psychosocial characteristics did not improve the researchers’ ability to determine the readmissions risk.

Patients taking sacubitril/valsartan to treat heart failure may experience survival benefit

An actuarial analysis found that patients who receive sacubitril/valsartan may have an increased life expectancy and reduced risk of death from cardiovascular causes or hospitalization for heart failure compared with patients who take enalapril.

ACC, Geisinger launch heart failure strategic initiative

The American College of Cardiology, Geisinger Health System and xG Health Solutions announced a new joint initiative to enhance the processes and outcomes of clinical care for patients with heart failure.

Pulmonary artery catheter use among heart failure patients increases despite guideline recommendations

Although guidelines recommend against the use of pulmonary artery catheters for routine management of heart failure, physicians have significantly increased their use of pulmonary artery catheters in recent years, according to an analysis of heart failure hospitalizations.

A Better Strategy for Stroke

Every year, more than 795,000 Americans suffer a stroke—with 665,000 people surviving the episode. The annual cost of stroke in the U.S. tops $33.6 billion (Circulation. 2015 ;e29-322.) and one out of six Americans will have a stroke in their lifetime. Stroke is our leading cause of disability.

FDA sends warning letter to St. Jude Medical regarding issues at Atlanta facility

The FDA sent a warning letter to St. Jude Medical regarding a facility in Atlanta where the company manufactures its CardioMEMS heart failure system. St. Jude Medical revealed the information in an 8-K filing to the Securities and Exchange Commission on Oct. 1.

Pages